Novartis AG (SWX: NOVN)

Switzerland flag Switzerland · Delayed Price · Currency is CHF
86.72
-0.32 (-0.37%)
Dec 20, 2024, 5:30 PM CET
2.48%
Market Cap 173.38B
Revenue (ttm) 42.18B
Net Income (ttm) 14.87B
Shares Out 2.00B
EPS (ttm) 7.25
PE Ratio 17.92
Forward PE 11.65
Dividend 3.30 (3.81%)
Ex-Dividend Date n/a
Volume 11,207,910
Open 86.06
Previous Close 87.04
Day's Range 85.77 - 86.96
52-Week Range 83.63 - 102.72
Beta 0.50
Analysts n/a
Price Target n/a
Earnings Date Jan 31, 2025

About Novartis AG

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and ... [Read more]

Sector Healthcare
Founded 1996
Employees 76,057
Stock Exchange SIX Swiss Exchange
Ticker Symbol NOVN
Full Company Profile

Financial Performance

In 2023, Novartis AG's revenue was $46.66 billion, an increase of 7.36% compared to the previous year's $43.46 billion. Earnings were $14.85 billion, an increase of 113.52%.

Financial numbers in USD Financial Statements

News

Some 330 jobs hit as Novartis closes Morphosys, WiWo reports

Swiss pharmaceutical group Novartis is winding up the German biotech company Morphosys, which it acquired at the beginning of the year, German news outlet WirtschaftsWoche reported on Thursday, saying...

3 days ago - Reuters

Novartis participates in Healthway Cancer Care Hospital ‘Celebrating Strength’ event championing breast cancer survivorship

In celebration of Breast Cancer Awareness Month, HealthwayCancer Care Hospital hosted the “Celebrating Strength: A Day for Breast Cancer Patients” last October 28, 2024.

5 days ago - BusinessMirror

Novartis and the pan-Canadian Pharmaceutical Alliance achieve milestone agreement for PLUVICTO™

Targeted radioligand therapy closer to public reimbursement for eligible Canadian patients with PSMA-positive metastatic castration-resistant prostate cancer MONTREAL , Dec. 13, 2024 /CNW/ - Novartis ...

9 days ago - Benzinga

Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report

The Institute for Clinical and Economic Review (ICER) has identified five prescription drugs whose price increases in 2023 lacked sufficient clinical evidence to justify the hikes. Gilead Sciences Inc...

9 days ago - Benzinga

Novartis: Time To Increase

Novartis' key growth drivers include higher investments in R&D and strategic early stake acquisitions. Find out why NVS stock is a Buy.

9 days ago - Seeking Alpha

Longer-term Novartis Kisqali® NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer

Basel, December 10, 2024 – Novartis today announced results from an updated analysis of the pivotal Phase III NATALEE trial of Kisqali® (ribociclib) that underscore the extended efficacy beyond the du...

12 days ago - GlobeNewsWire

Longer-term data for Novartis Scemblix® reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML

Basel, December 8, 2024 – Novartis today announced positive, longer-term results from the pivotal Phase III ASC4FIRST trial with Scemblix® (asciminib) showing superior major molecular response (MMR) r...

14 days ago - GlobeNewsWire

12 High-Yield Dividend Aristocrats To Weather The Coming 2025 Storm In Style

The S&P is up almost 28% in 2024, and many investors worry about a melt-up followed by a sharp correction like in 2022 or 2018. A 2025 market correction is likely, but low-volatility, high-yield Divid...

15 days ago - Seeking Alpha

Novartis Touts Encouraging Data From Late-Stage Study For Fabhalta In Rare Type Of Blood Disorder

On Friday, Novartis AG (NYSE: NVS) revealed topline results from the APPULSE-PNH Phase 3B study of Fabhalta (iptacopan) in adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who were switc...

16 days ago - Benzinga

Novartis reports positive Phase 3b data for Fabhalta in PNH

Novartis (NVS) reported positive Phase 3b data from a study of its drug Fabhalta for the treatment of paroxysmal nocturnal hemoglobinuria, or PNH. Read more here.

16 days ago - Seeking Alpha

New Phase IIIB data shows Novartis Fabhalta® improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from anti-C5 therapy

Basel, December 6, 2024 – Novartis today announced positive topline results from APPULSE-PNH, a Phase IIIB study evaluating the efficacy and safety of twice-daily oral monotherapy Fabhalta® (iptacopan...

16 days ago - GlobeNewsWire

Aurobindo Pharma arm Eugia Pharma receives USFDA approval for Pazopanib Tablets, 200 mg

Aurobindo Pharma Limited announced that its wholly-owned subsidiary, Eugia Pharma Specialities Limited, has secured final approval from the US Food and Drug Administration (USFDA) to manufacture and m...

17 days ago - Business Upturn

Monte Rosa Therapeutics: A First Assessment

Monte Rosa Therapeutics stock surged after a recent partnership with Novartis, despite limited clinical results. Can the rally continue? Read our full assessment on Seeking Alpha.

18 days ago - Seeking Alpha

Novartis cannot block generic of best-selling heart drug, US appeals court says

Novartis failed to convince a U.S. appeals court on Wednesday to halt MSN Pharmaceuticals' proposed generic of Novartis' blockbuster heart drug Entresto.

18 days ago - Reuters

Janux Therapeutics' Prostate Cancer Trial Data Exceeds Investor Expectations: Analyst

On Monday, Janux Therapeutics, Inc. (NASDAQ: JANX) revealed updated interim clinical data for its JANX007 clinical program . “These clinical data show substantial activity with JANX007 in 5L metastat...

19 days ago - Benzinga

Olema: Cash Infusion And Supply Agreement With Novartis Carries The Tide Forward

Olema Pharmaceuticals, Inc. entered into an agreement with Novartis to obtain KISQALI supply for the soon-to-be initiated phase 3 OPERA-02 study, targeting patients with ER+/HER2- metastatic breast ca...

20 days ago - Seeking Alpha

PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program

On Monday, PTC Therapeutics, Inc. (NASDAQ: PTCT) signed an exclusive global license and collaboration agreement with Novartis AG (NYSE: NVS) for its PTC518 Huntington’s disease program, which includ...

20 days ago - Benzinga

PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program

On Monday, PTC Therapeutics, Inc.  PTCT signed an exclusive global license and collaboration agreement with Novartis AG NVS for its PTC518 Huntington's disease program, which includes related molecule...

20 days ago - Benzinga

PTC Therapeutics Stock Soars on Novartis Licensing Agreement

Shares of PTC Therapeutics surged Monday when the pharmaceutical firm announced it struck a nearly $2 billion license and collaboration deal with Novartis.

20 days ago - Investopedia

Novartis' $2.9 Billion Huntington's Bet Sends PTC Stock Soaring Over 14%

Novartis' $2.9 Billion Huntington's Bet Sends PTC Stock Soaring Over 14%

20 days ago - GuruFocus